Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5 Head & Neck 2 Dermatologic 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 Classical hematology 1 CNS 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 293 Lenalidomide 162 Bortezomib 160 Cyclophosphamide 121 Calcium Dobesilate 118 Melphalan 116 fludarabine phosphate 75 carfilzomib 62 pomalidomide 57 Whole-Body Irradiation 57 Mycophenolic Acid 56 Granulocyte Colony-Stimulating Factor 55 Peripheral Blood Stem Cell Transplantation 54 Filgrastim 54 fludarabine 50 daratumumab 50 Tacrolimus 45 Busulfan 45 ixazomib 42 Thalidomide 37 Cyclosporine 32 Stem Cell Transplantation 29 dexamethasone acetate 28 Antilymphocyte Serum 26 dexamethasone 21-phosphate 23 plerixafor 21 elotuzumab 20 auricularum 20 belantamab mafodotin 19 Prednisone 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Immunotherapy × Plasma cell × Clear all

NCT03634800 2021-08-05

RISE-M

Weill Medical College of Cornell University

Phase 2 Terminated

6 enrolled 11 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡